More articles from Volume 32, Issue 1, 2016
Analysis of discrepancies of core needle biopsy and surgical specimens for accurate evaluation of hormonal receptors and epidermal growth factor receptor 2 status of invasive breast cancer patients
Elementi metaboličkog sindroma kod bolesnica sa subkliničkim hipotireoiduzmom
The etiology and incidence diastema median maxillary
The importance of Charlsonovog comorbidity index in assessing multiyear survival of patients with prostate cancer
Tubular adenoma of the gallblader
Article views
Elementi metaboličkog sindroma kod bolesnica sa subkliničkim hipotireoiduzmom
Vesna Popovic-Radinovic
Published: 01.12.2015.
Biochemistry
Volume 32, Issue 1 (2016)
pp. 1378-1384;
Abstract
Keywords
References
1.
Homa-Ir. Ispitana je veza TSH, FT4 i Anti TPO-At sa komponentama metaboilčkog sindroma, i pozitivna korelacija zabeležena je samo izmedju koncentracija TSH i glikemije, kao i pozitivna veza izmedju Anti TPO-At i vrednosti sistolnog i dijastolnog pritiska .Nije zabeležena korelacija izmedju FT4 i komponenata metaboličkog sindroma Prevalenca metaboličkog sindroma po IDF (OS ≥ 80 cm uz još bilo koja dva kriterijuma) iznosi 25 % kod zdravih osoba, a 62 % kod ispitanica sa subkliničkim hipotireoidizmom (i to 94 % u grupi sa DMT2 43 % u grupi bez DMT2.).U grupi sa subkliničkim hipotireoidizmom ima značajno više hipertenzija. (62).
2.
ali i 50 % zdravih kontrola ispunjava taj kriterijum, pa se postavlja pitanje,iako je mali uzorak,da li postajemo gojazna nacija? Sudeći po prevalenci MetS koja je 62 % kod osoba sa SH potrebno je da se kod osoba kod kojih je dijagnostikovan subklinički hipotireoidizam,obavezno uradi i dijagnostika u smislu otkrivanja metaboličkog sindroma, i OGTT. Važi i obrnuto, da se kod osoba sa utvrdjenim metaboiličkim sindromom obavezno proveri hormonski status tiroidne žlezde (naročito ako osoba sa MetSy ima i Diabates mell.tip2.) Preporučuje se i lečenje svih osoba sa subkliničkim hipotireoidizmom sa TSH ≥ 10 μmol/L, kao i onih sa TSH između 5 i 10 μmol/L, koji imaju pozitivna Anti TPO-At, po priznatim kritrerijumima (mlađe osobe, trudnice, osobe koje se leče od infertiliteta), ali i one koji imaju nezavisne faktore rizika za pojavu KVB kao što su dislipidemija. Literatura.
3.
Cooper D. Clinical Practice. Subclinical hypothyreoidisum. N Engl J Med. 2001;260–5.
4.
Biondi B, Cooper D. The clinical significance of subclinical thyroid dysfunction. Endocrine Reviews. 2008;(1):76–131.
5.
Surks M, Ortiz, Daniels G, Sawin C, Col N, Cobin R. Subclinical thyroid disease: Scientific review and guidelines for diagnosis and menagment. JAMA. 2004;(2):228–38.
6.
Wiersinga W. TSH: Is there a need to redefine the normal range? The thyroid and caridiovascular risk Georg Thieme Verlag. 2005;24–9.
7.
Ross D. Serum TSH measurement for assesment of thyroid function and disease. Endocrinol Metab Clin North Am. 2001;245–64.
8.
Surks M, Goswami G, Daniels G. The thyreotropin reference range should remain unchanged. Journ Clin Endocrin Metab. 2005;(9):5489–96.
9.
Gharib H, Tutle R, Baskin H, Fishlh, Singer P, Msdermott M. Consesus statament : Sublcilical thyroid dysfunction: a joint stetementon menagment from THE AACE,the ETA and the ES. JCEM. 2005;(1):581–858.
10.
Canarais G, Manowitz N, Mayor G, Ridgway E. The Colorado Thyroid disaes prevalence study. Arh Intern Med. 2000;526–3423.
11.
Duntas L. Changes in lipid profile in overt subclinical hypothyroidism. The thyroid and cardiovascular risk. 2005;37–43.
12.
Diekman T, Lansberg P, Kastelein J, Wirzinga W. Prevalence and correction of hypothiroidism in a large cohort of pacient referred for dyslipidemia. Arhives of Internal Medicine. 1995;(14):1490–5.
13.
Duntas L. Thyroid disease and lipids. Thyroid. 2002;287–93.
14.
Iqbal A, Jorde R, Figenschau Y. Serum lipid levels in relation to serum thyroid stimulating hormone and the effect of thyroxine treatment od serum lipid levels in subject with sublinical hypothiroidism :the Tromso Study. J Inter Med. 2006;(1):53–61.
15.
Biondi B, Klein I. Cardiovascular abnormalities in subclinical and overt hypothyroidism The thyroid and cardiovascular risk. 2005;30–4.
16.
Fusio S, Palmieri E, Lombardi G, Biondi B. Hypothyroidism as a risk factor for cardiovascular disease. Recent Prog Horm Res. 2004;31–50.
17.
Rodondi N, Den Elzen W, Bauer D, Cappola A, Razvi S, Walsh J. Subclinical hypothyroidism and risc of coronary heart disease and mortality. JAMA. 2010;(12):1365–74.
18.
Manzani F, Di Bello V, Caraccio N, Bertini A, Giorgi D, Giusti C, et al. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism :double blind, placebo controlled study. JCEM. 2001;(3):1110–5.
19.
Dagre A, Lekakis J, Protogerou A, Douridas G, Papaionnou T, Tryfonopoulos D. Abnormal entotheliel function in female patients with hypothyroidism and bordeline thyroid function. Int J Cardiol. 2007;(3):332–8.
20.
Crowly W, Ridgway E, Bough E, Francis G, Daniels G, Kourides I. Noninvasive evaluation of cardiac function in hypothyroidism : response to gradual thyroxine replacement. N Engl J M. 1997;1–6.
21.
Grundy S, Brewar H, Cleeman J, Smith S, Lenfant C. Definition of metabolic syndrome: Report of National Heart,Lung and Blood Institute/American Heart assotiation/.Conference on scientific issues relatided to deffinition. Circualtion. 2004;(3):433–3837.
22.
International Diabetes Federation Metabolic syndrom.
23.
Groop L, Cha Ndola T, Bruner E, Marmot M. Chronic stres at work and the metabolic syndrome: prospective study. Internat.l Journal of Obesity. 2000;332–521.
24.
Narasimhan M, Raynor J. Evidence based perspectiveon metabolic syndrome and use of antipshychotics drug. Beneffit Trends. 2010;77–88.
25.
Dessein P, Gonzales-Gay M, Woodiwiss A, Joffe B, Norton G, Solomon A. The impact of the metaboloc syndrome on cariovascular risc and disease in Rheumatoid arthritis. Future rheumatology. 2008;(4):335–9.
26.
Gisondi P, Tessari G, Conti A. Prevalence od metabolic syndrome in patients with psoriasis : a hospital-based casecontrole study. British Jornal of dermatology. 2007;68–73.
27.
Garduno-Garcia J Dej A, Garcia U, Lopez-Carasco G, Medoza P, Mehta M, Arellano-Campos R, et al. TSH and free thyroxin concentration are associated with differing metabolic markers in euthyroid subjects. Eur J Endocrin. 2010;(2):273–8.
28.
Erdogan M, Cantazoglu A, Ganidagli S, Kulaksizoglu M. Metabolic syndrome prevalence in subclinical and overt hypothyreoid patients and the relation among metabolic parameters. J Endocrin Invest. 2011;(7):488–92.
29.
Tehrani R, Tohidi F, Rostami F, Asgaris M, Azizi F. The association between subclinical hypothyreoidism and metabolic syndrome: a population based stud. IJEM. 2011;(1):98–105.
30.
Agarwal G, Shudakar M, Sing M, Senthial N, Rajerdam A. The prevalence of thyroid dysfunction among South Indian women with metabolic syndrome. Jour Clin Diag Reaserch. 2011;(2):213–6.
Citation
Copyright
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Article metrics
Google scholar:
See link
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
